KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis
KIF20A drives primary anti-PD-1 resistance in NSCLC through PD-L1 suppression and independently predicts poor survival. The KIF20A/PD-L1 signature stratifies patient risk, positioning KIF20A as both a prognostic biomarker and a therapeutic target to overcome immunotherapy resistance.
Authors
- Jing Cao (ORCID: https://orcid.org/0000-0002-9425-9982)
- Xiang Wang
- Lei Chen (ORCID: https://orcid.org/0000-0002-1498-718X)
- Li Lin (ORCID: https://orcid.org/0000-0003-2783-1114)
- Tianyu Su
Institutions
- Xuzhou Medical College (CN)
- Fudan University Shanghai Cancer Center (CN)
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1186/s12885-025-15221-6
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05